XTANT Aktie

>XTANT Aktienkurs

0.429 EUR (TradegateBSX)

Ask: 0.442 EUR / 3389 Stück

Bid: 0.416 EUR / 3606 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

XTANT Aktie über LYNX handeln

Intraday

1 Jahr

>XTANT Performance

1 Woche: -9,3%

1 Monat: -16,2%

3 Monate: -32,7%

6 Monate: -22,4%

1 Jahr: -0,2%

laufendes Jahr: -36,4%

>XTANT Aktie

Name:

XTANT MEDICAL HLDGS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US98420P3082 / A2JDJS

Symbol/ Ticker:

XMS (Frankfurt)

Kürzel:

FRA:XMS, ETR:XMS, XMS:GR

Index:

Webseite:

https://xtantmedical.com/

Profil:

Xtant Medical Holdings Inc. is a leading company in the medical device sector, specializing in the development and distribution of regenerative medicine products and surgical implants. The core purpose of the company is to improve patient outcomes th..
>Volltext..

Marktkapitalisierung:

64.57 Mio. EUR

Unternehmenswert:

83.18 Mio. EUR

Umsatz:

115.29 Mio. EUR

EBITDA:

9.44 Mio. EUR

Nettogewinn:

1.52 Mio. EUR

Gewinn je Aktie:

0.01 EUR

Schulden:

28.14 Mio. EUR

Liquide Mittel:

9.22 Mio. EUR

Operativer Cashflow:

6.74 Mio. EUR

Bargeldquote:

0.3

Umsatzwachstum:

10.9%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

XTANT

Letzte Datenerhebung:

05.04.26

>XTANT Kennzahlen

Aktien/ Unternehmen:

Aktien: 140 Mio. St.

Frei handelbar: 84%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 232

Umsatz/Mitarb.: 0.44 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 169.59%

Bewertung:

KGV: 49.93

KGV lG: 37.94

KUV: 0.64

KBV: 1.42

PEG-Ratio: -

EV/EBITDA: 8.81

Rentabilität:

Bruttomarge: 62.02%

Gewinnmarge: 1.32%

Operative Marge: 4.77%

Managementeffizenz:

Gesamtkaprendite: 1.71%

Eigenkaprendite: 3.64%

>XTANT Peer Group

Gesundheit, Neurologische- & psychische Behandlung/ Medizin, Medizinprodukte & -technik/ Implantate/ Wundpflege

>XTANT Chart & Kurs - Tradegate

>XTANT News

31.03.26 - 16:57	Xtant outlines $95M-$99M 2026 revenue outlook as Companion Spine divestiture and Q-code license revenue roll off (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.26 - 13:12	Xtant Medical beats top-line and bottom-line estimates; gives FY26 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.26 - 13:03	Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results (PR Newswire)
	Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to......

03.03.26 - 07:12	Xtant Medical stellt strategische Neuausrichtung auf regenerative Biologika vor (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.12.25 - 14:03	Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft (PR Newswire)
	nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mont., Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a......

01.12.25 - 22:09	Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine (PR Newswire)
	BELGRADE, Mont., Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that the company has completed its previously announced sale of......

11.11.25 - 16:57	Xtant Medical reiterates $131M–$135M 2025 revenue guidance as company pursues strategic asset sale and ramps orthobiologics innovation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 15:30	Earnings Call: Xtant Medical übertrifft Prognosen in Q3 2025 – Aktie legt deutlich zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.25 - 22:30	Xtant Medical Reports Third Quarter 2025 Financial Results (PR Newswire)
	Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Growth of 11%-15% over FY24 Previously Announced Sale of Certain Hardware Assets and OUS......

05.11.25 - 14:06	Xtant Medical Announces Commercial Launch of CollagenX™ (PR Newswire)
	Launch further expands Xtant's biologics product portfolio to include surgical wound closure BELGRADE, Mont., Nov. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal,......

04.09.25 - 15:01	Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
	BELGRADE, Mont., Sept. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO, and Scott Neils,......

12.08.25 - 16:45	Xtant Medical raises 2025 revenue outlook to $131M–$135M as it divests noncore assets and advances biologics platform (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 14:06	Xtant Medical GAAP EPS of $0.02 beats by $0.03, revenue of $35.4M beats by $4.05M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 13:18	Xtant Medical beats top-line and bottom-line estimates; raises FY25 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 13:01	Xtant Medical Reports Second Quarter 2025 Financial Results (PR Newswire)
	Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont., Aug. 12, 2025 /PRNewswire/ -- Xtant Medical......

06.08.25 - 22:03	Xtant Medical to Attend the CG 45th Annual Growth Conference (PR Newswire)
	BELGRADE, Mont., Aug. 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO and Scott Neils, CFO......

05.08.25 - 14:03	Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
	BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results......

28.05.25 - 14:06	Xtant Medical Announces the Launch of OsteoFactor Pro™ (PR Newswire)
	Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont., May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders,......

13.05.25 - 02:39	Xtant Medical outlines 8–11% revenue growth target for 2025 as company completes vertical integration and launches new products (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.25 - 23:00	Xtant Medical files to sell 73.11M shares of common stock for holders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram